Literature DB >> 6087781

Serum angiotensin converting enzyme in Crohn's disease, ulcerative colitis and peptic ulceration.

G M D'Onofrio, S Levitt, K F Ilett.   

Abstract

Serum angiotensin converting enzyme (ACE) activities were determined in patients with different types of inflammatory disease of the gastrointestinal tract, in patients with peptic ulcer, and in healthy volunteer subjects. ACE activity in serum was measured by its in vitro ability to cleave hippuric acid from the synthetic tripeptide hippuryl-L-histidyl-L-leucine. The hippuric acid so formed was quantified by high performance liquid chromatography and results are expressed as nmol hippuric acid produced/ml plasma/min. ACE activity was 27.4 +/- 7.7 (mean +/- SD, n = 37) in control subjects and was not related to age or sex. Compared to controls, patients with ulcerative colitis had similar ACE values (26.5 +/- 7.7, n = 16) while, surprisingly, there was a significant (p less than 0.01) increase in the enzyme in those with active peptic ulcers (33.8 +/- 8.8, n = 21) irrespective of whether the site of ulceration was gastric or duodenal. In a mixed group of patients with active and inactive Crohn's disease, ACE activity (24.8 +/- 7.2, n = 19) was not different from controls. However, ACE activity was significantly (p less than 0.02) depressed in active Crohn's disease (19.8 +/- 7.3, n = 8) compared to either control subjects or patients with inactive disease (28.4 +/- 6.3, n = 9). There was wide inter-patient variability in ACE levels and hence the diagnostic value of random measurements of this enzyme in Crohn's disease is limited.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6087781     DOI: 10.1111/j.1445-5994.1984.tb03580.x

Source DB:  PubMed          Journal:  Aust N Z J Med        ISSN: 0004-8291


  2 in total

Review 1.  Symptomatic gastrointestinal sarcoidosis: case report and review of the literature.

Authors:  Ripudaman S Beniwal; Oscar W Cummings; Won Kyoo Cho
Journal:  Dig Dis Sci       Date:  2003-01       Impact factor: 3.199

2.  Use of enterally delivered angiotensin II type Ia receptor antagonists to reduce the severity of colitis.

Authors:  Manabu Okawada; Hiroyuki Koga; Scott D Larsen; Hollis D Showalter; Anjanette J Turbiak; Xiaohong Jin; Peter C Lucas; Elke Lipka; John Hillfinger; Jae Seung Kim; Daniel H Teitelbaum
Journal:  Dig Dis Sci       Date:  2011-03-12       Impact factor: 3.199

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.